Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm, Residual × Vitamin D × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 9 Prostatic Neoplasms 2 Obesity 2 Vitamin D Deficiency 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycystic Ovary Syndrome 1 Peripheral Nervous System Diseases 1 Neurofibromatosis 1 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Kidney Neoplasms 1 Helicobacter Infections 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

blinatumomab 7 Cyclophosphamide 6 Rituximab 5 Lenalidomide 5 Dexamethasone 5 Azacitidine 5 venetoclax 4 fludarabine 4 fludarabine phosphate 3 Cytarabine 3 tislelizumab 2 thymoglobulin 2 obinutuzumab 2 daratumumab 2 Whole-Body Irradiation 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Methotrexate 2 Melphalan 2 Immunotherapy 2 Imatinib Mesylate 2 Docetaxel 2 Decitabine 2 Clofarabine 2 Cladribine 2 Calcium Dobesilate 2 Busulfan 2 treosulfan 1 trastuzumab deruxtecan 1 tisagenlecleucel 1 talquetamab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡